Scopus Biopharma Inc (SCPS) USD0.001

Sell:$0.00Buy:$0.00No change

Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:$0.00
Buy:$0.00
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of its immuno-oncology programs for treatment-resistant cancers. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The Company is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.

Key people

Joshua R. Lamstein
Chairman of the Board, Principal Executive Officer
Robert J. Gibson
Vice Chairman of the Board, Treasurer, Secretary
Alan M. Horsager
President - Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics
Aharon Schwartz
Executive Chairman of Scopus BioPharma Israel Ltd
Ira Scott Greenspan
Director
David A. Buckel
Independent Director
Raphael Hofstein
Independent Director
David Weild
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8091711015
  • Market cap
    $12,630.00
  • Employees
    13
  • Shares in issue
    42.08m
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.